Physicochemical Properties
| Molecular Formula | C32H34N6O4S |
| Molecular Weight | 598.715165615082 |
| CAS # | 2522594-49-4 |
| PubChem CID | 162649581 |
| Appearance | Typically exists as solid at room temperature |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Heavy Atom Count | 43 |
| Complexity | 905 |
| Defined Atom Stereocenter Count | 0 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | With IC50 values of 11.54±0.18, 0.91±0.31, and 8.21 ± 0.50, respectively, against MCF-7, PC3, MGC-803, PC9, and WPMY-1 (a normal human prostate stromal myofibroblast cell line), antitumor agent-55 (compound 5q) shown inhibitory activity[1]. The growth of PC3 cells is considerably inhibited by antitumor agent-55 (0-10 μM, 24-72 hours) in a dose- and time-dependent manner [1]. In a dose-dependent way, the antineoplastic drug 55 (0–4 μM, 24 hours) raises the G1/S phase population and enhances the expression of the p27 protein [1]. The anticancer drug 55 (0–4 μM, 24-48 h) concurrently activates two apoptotic signaling pathways, causing dose-dependent ROS generation and PC3 cell apoptosis [1]. In a dose-dependent manner, the antineoplastic drug 55 (0-1 μM, 48 hours) significantly inhibits PC3 cell migration and wound healing [1]. |
| Cell Assay |
Cell viability assay Cell Types: PC3 cells [1] Tested Concentrations: 0, 0.156, 0.313, 0.625, 1.25, 2.5, 5, 10 μM Incubation Duration: 24, 48, 72 hrs (hours) Experimental Results: Dramatically inhibited the proliferation of PC3 cells over time As time goes by, fewer and fewer colonies are formed. Cell cycle analysis Cell Types: PC3 cells [1] Tested Concentrations: 0, 1, 2, 4 μM Incubation Duration: 24 h Experimental Results: At high concentrations, the G1/S phase population in PC3 cells increased Dramatically and the G2/M content diminished. Western Blot Analysis Cell Types: PC3 cells [1] Tested Concentrations: 0, 1, 2, 4 μM Incubation Duration: 24 h, 48 h Experimental Results: p27 protein expression increased in a dose-dependent manner, and the expression of pro-apoptotic Bax increased Dramatically and P53, while the expression of anti-apoptotic Bcl-2 was down-regulated, and the expression of cleaved caspase 3/9 and cleaved PARP was Dramatically increased in a dose-dependent manner. Apoptosis analysis Cell Types: PC3 cells [1] Tested Concentrations: 0, 1, 2, 4 μM Incubatio |
| References |
[1]. Lu N, Huo JL, Wang S, Yuan XH, Liu HM. Drug repurposing: Discovery of troxipide analogs as potent antitumor agents. Eur J Med Chem. 2020;202:112471. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6702 mL | 8.3511 mL | 16.7023 mL | |
| 5 mM | 0.3340 mL | 1.6702 mL | 3.3405 mL | |
| 10 mM | 0.1670 mL | 0.8351 mL | 1.6702 mL |